Study of TAK-664 for people with primary immunodeficiency who haven't had immunoglobulin treatment
Part of Genetic & congenital, Immune system & allergy clinical trials.
This study tests a new medicine called TAK-664, which is a type of immunoglobulin (antibody) replacement therapy, in people with primary immunodeficiency who have never received immunoglobulin treatment before. The goal is to see if it can help prevent infections and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 6 years old.
- You have a primary immunodeficiency that affects your ability to make antibodies (infection-fighting proteins).
- You have not received immunoglobulin (antibody) replacement therapy before.
- Your current antibody (IgG) level is low (400 mg/dL or less).
- You are willing to use effective birth control if you could become pregnant, and you are not pregnant or breastfeeding.
- You do not have certain medical conditions, like severe kidney problems, active infections, or a history of blood clots or certain cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new intravenous immunoglobulin (IVIG) treatment for patients with primary immunodeficiency diseases, such as common variable immune deficiency (CVID) or X-linked agammaglobulinemia (XLA). It aims to see if this medicine is safe and works well to prevent infections.
This study is a safety check for people with primary immunodeficiency who are already using a specific immune globulin treatment given under the skin. It looks at medical records to see if any side effects occurred.
This program offers continued access to the study drug TAK-881 for people with primary immunodeficiency diseases who have already completed a related study. It is designed for those who are benefiting from the treatment and have no safety concerns.
This study tests a new investigational drug called TAK-411 for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). It is for people who have already responded to immunoglobulin therapy and are on a stable dose.
This study examines how well immunoglobulin replacement therapy works in people with primary antibody immunodeficiency—a rare condition where the body cannot make enough antibodies to fight infections. Researchers will also study immune system changes to understand treatment response better.
This trial tests a new medicine (BP-SCIG 20%) given under the skin to help children and adults with primary immunodeficiency who have trouble making antibodies. It aims to see if the medicine is safe and works well to prevent infections.
Hear when a new Primary Immunodeficiency Diseases (PID) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.